Unlocking the Power of CHO Cell Lines By Sequencing

Chinese hamster ovary cell lines, or CHO cell lines, are mammalian cells derived from the ovary of the Chinese hamster. Today these cell lines are widely used in biological research and in the production of therapeutic proteins. Currently about 130 approved and marketed therapeutic proteins are manufactured in mammalian cells, accounting for most of the therapeutic protein market. Sequencing the CHO genome unlocks new information; thus, accelerating the discovery and development of new recombinant protein therapeutics by increasing production of CHO cell lines—used in many pharmaceutical expression systems— and by reducing production costs.

GT Life Sciences, Inc., a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, and BGI (previously known as the Beijing Genomics Institute), the largest genomics organization in the world, announced that they have successfully completed, for the first time, the sequencing of the Chinese hamster ovary (CHO-K1) genome.

Early access of the genome is now available. The early access program allows you to immediately access the CHO-K1 cell line sequence and annotations—before publications have been written, submitted, or gone to press—giving you a distinct advantage over others not offered early access. This program and the following sequencing services are sold and conducted by BGI alone.

          Get immediate access to CHO-K1 sequence and annotations

             BGI offers de novo sequencing of your own CHO cell lines.

             We use CHO-K1 as the reference genome.